EPIVISION is a biotechnology company developing next-generation liquid biopsy solutions for early cancer detection and monitoring. Its proprietary EPINUC™ platform analyzes epigenetic signatures in blood samples to identify cancer-related signals that conventional mutation-based tests may miss, reading biological signals in blood that conventional liquid biopsies miss from as little as 1 mL of plasma. The company combines advanced molecular science with clinical innovation to improve cancer diagnostics and support smarter clinical trials.
For more details, see Epivision.